TGR-1202- a new generation PI3K delta inhibitor for CLL

Javier Pinilla-Ibarz

Javier Pinilla-Ibarz, MD, PhD from the H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL discusses a new generation PI3K delta inhibitor used in chronic lymphocytic leukemia (CLL) called TGR-1202. Surprisingly TGR-1202 has a significantly better tolerability profile compared to other PI3K delta inhibitors. This interview was recorded at the International Workshop on Chronic lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video